Aura Biosciences, Inc. (AURA)

NASDAQ: AURA · IEX Real-Time Price · USD
18.12
-0.23 (-1.25%)
Sep 30, 2022 4:00 PM EDT - Market closed
-1.25%
Market Cap 530.44M
Revenue (ttm) n/a
Net Income (ttm) -51.76M
Shares Out 29.27M
EPS (ttm) -4.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 96,765
Open 17.13
Previous Close 18.35
Day's Range 16.84 - 18.60
52-Week Range 11.98 - 26.16
Beta n/a
Analysts Buy
Price Target 31.37 (+73.1%)
Earnings Date Aug 11, 2022

About AURA

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts. [Read more...]

Industry Biotechnology
IPO Date Oct 29, 2021
Employees 52
Stock Exchange NASDAQ
Ticker Symbol AURA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for AURA stock is "Buy." The 12-month stock price forecast is 31.37, which is an increase of 73.12% from the latest price.

Price Target
$31.37
(73.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Tr...

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indicati...

4 days ago - Business Wire

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (...

BOSTON--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indicat...

5 days ago - Business Wire

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (A...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

3 weeks ago - Business Wire

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

1 month ago - Business Wire

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational High...

BOSTON--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indicati...

1 month ago - Business Wire

Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolo...

2 months ago - Business Wire

JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer"

JMP Securities has initiated the coverage on Aura Biosciences Inc (NASDAQ: AURA) with a Market Outperform rating and a $26 risk-adjusted price target. Aura is developing a targeted virus-like drug conju...

2 months ago - Benzinga

Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate

Shares of Aura Biosciences Inc. were up 11.3% in premarket trading on Thursday after the company said it received a Fast-Track designation from the Food and Drug Administration for its experimental blad...

3 months ago - Market Watch

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Mus...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolo...

3 months ago - Business Wire

Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer

Aura Biosciences Inc (NASDAQ: AURA) reported data from a retrospective analysis that assessed the visual acuity after plaque radiotherapy treatment compared with prospective data in early-stage choroida...

3 months ago - Benzinga

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Rad...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

3 months ago - Business Wire

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Soc...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

3 months ago - Business Wire

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibito...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

4 months ago - Business Wire

Aura Biosciences to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

4 months ago - Business Wire

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highl...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

4 months ago - Business Wire

Aura Biosciences Presents Preclinical Data Highlighting AU-011's Anti-Tumor Activity in Choroidal Metastasis, an Addi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

4 months ago - Business Wire

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

4 months ago - Business Wire

Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Op...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

6 months ago - Business Wire

Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uvea...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

6 months ago - Business Wire

Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

6 months ago - Business Wire

Aura Biosciences to Present Preclinical Data Highlighting AU‑011's Potential to Target a Broad Number of Tumor Types ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

6 months ago - Business Wire

Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

7 months ago - Business Wire

Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

7 months ago - Business Wire

Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

7 months ago - Business Wire

Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highl...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncolog...

10 months ago - Business Wire